A-3 Price List - Leukemia Lymphoma Agents-BTKI.xlsx
XLSX spreadsheet 45 KB Posted
- Solicitation number
- HT9402-24-Q-9301
- Issued by
-
Defense Health Agency
About this file
This document is a Request for Quotation (RFQ) related to the Department of Defense (DoD) Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program. The DoD is soliciting quotes from industry for pharmaceutical agents within certain drug classes, including Leukemia and Lymphoma Agents: Bruton Tyrosine Kinase Inhibitors, to be considered for placement on the DoD Uniform Formulary (UF) at the August 2024 Pharmacy and Therapeutics (P&T) Committee meeting.
The RFQ provides details on the UF BPA and UF ADP agreements that may be awarded based on the P&T Committee's formulary decisions. Key details include the requirement for manufacturers to submit quotes by June 13, 2024, information on formulary placement scenarios and pricing bands, and requirements for additional discounts and refunds for TRICARE retail prescriptions. The RFQ also includes instructions for the pre-quote teleconference on April 24, 2024 and the submission of responses to clinical questions.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| RFQ HT9402-24-Q-9301 CR.pdf | ||
| Amendment 0001 CR.pdf | ||
| August 24 DoD P and T Reporting Data.xlsx | XLSX spreadsheet | |
| A-3 Price List - Antipsychotic Agents - Parkinsons.xlsx | XLSX spreadsheet | |
| RFQ HT9402-23-Q-9301 CR.pdf | ||
| NDC Price List FAQ Class Review.pdf | ||
| A-3 Price List - Antilipidemics-1 - Statins.xlsx | XLSX spreadsheet | |
| A-3 Price List - Antilipidemics-1 - Non-Statins and Combos.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2024 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 |
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Based on available government prices and historical information, the band of prices for net ingredient cost may trigger formulary considerations.
Scenario 1:
Uniform Formulary and/or Tier 2 before step therapy for the CLL/SLL indication with a specialist bypass (no PA required) for hematologists and oncologists may be considered if ingredient cost is ≤ $6,000 average per 30 days of therapy.
Uniform Formulary and/or Tier 2 after step therapy may be considered if ingredient cost is > $6,000 average per 30 days of therapy.
Scenario 2:
Uniform Formulary and/or Tier 2 may be considered if ingredient cost is ≤ $7,000 average per 30 days of therapy. Agents meeting the Uniform Formulary price band may be considered for a specialist bypass (no PA required) for hematologists and oncologists.
Non-Formulary and/or Tier 3 may be considered if ingredient cost is > $7,000 average per 30 days of therapy.
All Scenarios: Agents with RFQ not submitted or selected may be designated non-step preferred.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Class Review
| #1 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #2 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #3 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #4 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #5 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order | |||
| 1.00 | ||||||||
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | 1.00 | NO QUOTE | |||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | 1.00 | NO QUOTE | |||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | 1.00 | NO QUOTE | |||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | 1.00 | NO QUOTE | |||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | 1.00 | NO QUOTE | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #6 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #7 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #8 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #9 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #10 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | ||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent may be placed before the step. | ||||||||
| Scenario 1 | 244LLBTG1UFBS1M | Uniform Formulary | ||||||
| Before Step Thereapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 244LLBTG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: No step therapy. One or more. | ||||||||
| Scenario 2 | 244LLBTG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 244LLBTG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Discount Table for the August 2024 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 |
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.
Based on available government prices and historical information, the band of prices for net ingredient cost may trigger formulary considerations.
Scenario 1:
Uniform Formulary and/or Tier 2 before step therapy for the CLL/SLL indication with a specialist bypass (no PA required) for hematologists and oncologists may be considered if ingredient cost is ≤ $6,000 average per 30 days of therapy.
Uniform Formulary and/or Tier 2 after step therapy may be considered if ingredient cost is > $6,000 average per 30 days of therapy.
Scenario 2:
Uniform Formulary and/or Tier 2 may be considered if ingredient cost is ≤ $7,000 average per 30 days of therapy. Agents meeting the Uniform Formulary price band may be considered for a specialist bypass (no PA required) for hematologists and oncologists.
Non-Formulary and/or Tier 3 may be considered if ingredient cost is > $7,000 average per 30 days of therapy.
All Scenarios: Agents with RFQ not submitted or selected may be designated non-step preferred.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Class Review
| #1 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #2 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #3 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #4 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #5 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #6 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #7 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #8 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #9 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #10 | DOD Uniform Formulary Class: | LEUKEMIA AND LYMPHOMA AGENTS | P&T Committee Meeting: | August 7-8, 2024 | |||
| DOD Uniform Formulary Subclass: | BRUTON TYROSINE KINASE INHIBITORS | Quotes due: | June 13, 2024 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Branded Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent may be placed before the step. | ||||||||||
| Scenario 1 | 244LLBTG1T2BS1M | Tier 2 | ||||||||
| Before Step Therapy | 1 or more | |||||||||
| 244LLBTG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 244LLBTG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: No step therapy. One or more. | ||||||||||
| Scenario 2 | 244LLBTG1T21M | Tier 2 | 1 or more | |||||||
| 244LLBTG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .